Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    MET molecular structure

    MET Stats & Data

    Methylethyltryptamine
    PubChem
    MW202.30
    FormulaC13H18N2
    LogP2.9
    IUPACN-ethyl-2-(1H-indol-3-yl)-N-methylethanamine
    SMILESCCN(C)CCC1=CNC2=CC=CC=C21
    InChIKeyMYEGVMLMDWYPOA-UHFFFAOYSA-N
    Chemical Class Substituted tryptamine
    Psychoactive Class Psychedelic

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor partial agonist
    5-HT2C receptor partial agonist
    Other
    serotonin releasing agent (weak)

    History & Culture

    MET was first documented in scientific literature in 1981, appearing in Michael Valentine Smith's book "Psychedelic Chemistry." The compound subsequently received a brief entry in Alexander Shulgin's 1997 publication "TiHKAL" (Tryptamines I Have Known and Loved), though it did not receive extensive characterization in that work. The substance emerged on the European drug market as a novel designer drug in 2014, marking its first appearance in recreational contexts. By mid-2016, MET had become available through online research chemical vendors, where it continues to be distributed for recreational and entheogenic purposes.

    Toxicity

    PsychonautWiki

    The toxicity and long-term health effects of recreational MET use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because MET is a research chemical with very little history of human usage. Anecdotal evidence from people within the community who have tried MET suggest that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.

    Effect Profile

    Curated + 9 Reports
    Psychedelic 6.0

    Strong visuals with mild headspace and body load

    Visual Intensity×3
    10
    Headspace Depth×3
    4
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    4

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Smoked/Vaporized
    0-1 minutes
    1-4 minutes
    10-19 minutes
    19-40 minutes
    19 minutes - 1.0 hours
    Oral
    19-45 minutes
    30 minutes - 1.0 hours
    1-2 hours
    1-2 hours
    1-3 hours
    Insufflated
    4-15 minutes
    10-19 minutes
    30 minutes - 1.5 hours
    45 minutes - 1.5 hours
    30 minutes - 2.0 hours

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    Psilocybin
    Psilocin
    Mescaline
    DMT
    5-MeO-DMT
    2C-B
    2C-E

    Experience Report Analysis

    Erowid
    14 Reports
    9 Single-substance
    2006–2025 Date Range
    13 With Age Data
    6 Effects Detected

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 14 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 11 of 14
    • Female 2 of 14
    • Not Specified 1 of 14

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 9 experience reports (9 single-substance Erowid)

    9 Reports
    6 Effects Detected
    6 Positive
    0 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 9 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 6

    Visual Distortions 7 of 9 70%
    Closed-Eye Visuals 5 of 9 70%
    Empathy 4 of 9 70%
    Music Enhancement 4 of 9 70%
    Stimulation 4 of 9 70%
    Euphoria 3 of 9 70%

    Adverse Effects 0

    Real-World Dose Distribution

    Erowid

    From 15 of 21 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Smoked (n=15)

    Median: 25.0mg 25th: 17.5mg 75th: 30.0mg 90th: 33.0mg

    Form / Preparation

    Most common forms and preparations, as a share of the 11 reports that give one

    Too few reports for bars: these forms come from 11 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Powder / Crystals 10 of 11

    Redose Patterns

    Redosing behavior across 11 reports

    3 of 11 Redosed
    1.6 Avg Doses
    60m Median Interval

    Too few reports for a chart: redosing is known from 11 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Single dose 8 of 11
    • Redosed 3 of 11

    Legal Status

    Country Status Notes
    Germany NpSG (Controlled) Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to distribute, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalty.
    Japan Controlled Designated as a controlled substance as of March 20, 2023.
    New Zealand Class C Controlled as a structural analogue of DMT under New Zealand's drug legislation.
    Switzerland Uncontrolled Not listed under Buchstabe A, B, C, or D of Swiss controlled substances legislation. May be considered legal for possession.
    United Kingdom Class A Controlled under the Misuse of Drugs Act 1971 via a generic clause added in 1977 that covers tryptamine derivatives modified by alkyl substitution at the nitrogen atom of the side chain.
    United States Unscheduled (Analogue Act may apply) MET is not specifically scheduled under the Controlled Substances Act. However, it may be considered a controlled substance analogue of DMT or DET, meaning sales for human consumption or possession with intent to ingest could potentially be prosecuted under the Federal Analogue Act.
    ← Back to MET